Qingqing Zhu1,2, Jianjun Zhang2, Jie Liu2* and Bao Song3*
1School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, China
2Department of Respiratory Internal, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, China
3Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, China
Metronomic chemotherapy is a therapeutic strategy that treats tumors through frequent low-dose drug administration. It has many mechanisms including chemotherapy, immunotherapy, and antiangiogenesis, and has the advantages of short therapy interval and slight toxic reaction. Traditional chemotherapy takes the Maximum Tolerated Dose (MTD) as the standard for a drug administration cycle. By contrast, metronomic chemotherapy mainly targets neovascularization of tumors and activates anti-tumor immunity in the body. Oral vinorelbine is an appealing agent, particularly as part of combination regimens containing platinum derivatives, although it can have a role as a single-agent treatment as well. As a tubulin inhibitor, Vinorelbine is regarded as the best option in metronomic chemotherapy for non-small cell lung cancer. Clinical application studies include oral vinorelbine monotherapy and/or combination with platinum-based chemotherapy, combination with radiotherapy, combination with immunotherapy and so on. Its safety profile is generally favorable and its route of administration is generally preferred by patients receiving chemotherapy. Compared to intravenous injection of vinorelbine and other antineoplastic agents, oral vinorelbine has been reported to be advantageous in terms of cost savings. This article clarifies the mechanism and clinical application of metronomic chemotherapy with vinorelbine in advanced non-small cell lung cancer.
Metronomic chemotherapy; Vinorelbine; Non-small cell lung cancer (NSCLC); Antiangiogenesis
Zhu Q, Zhang J, Liu J, Song B. Advances in Oral Vinorelbine Metronomic Chemotherapy for NonSmall Cell Lung Cancer. Clin Oncol. 2018; 3: 1550.